Last reviewed · How we verify
L-Isoleucine (ISOLEUCINE)
L-Isoleucine is a small molecule with unknown target and drug class. It is not FDA approved for any indications. The commercial status of L-Isoleucine is unknown, and it is not clear if it is patented or generic. There is limited information available on its pharmacokinetic properties, including half-life and bioavailability. Further research is needed to understand its potential therapeutic applications and safety profile.
At a glance
| Generic name | ISOLEUCINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
- Erythema at infusion site
- Phlebitis at infusion site
- Thrombosis at infusion site
- Nausea
- Generalized flushing
- Fever
- Venous irritation
Key clinical trials
- Pre-Surgical Immunonutrition's Effect on Colorectal Surgery (NA)
- Isoleucine Addition Treatment Effects in a Controlled Diet Study (NA)
- Essential Amino Acids and Parkinsons Disease (PHASE1)
- SMART Diets for MASLD (PHASE2)
- SmART-TBI: Supplementation With Amino Acid Rehabilitative Therapy in TBI (NA)
- Prandial Metabolic Phenotype in Adults (NA)
- Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients (PHASE3)
- Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |